How Pierre Fabre Laboratories Enhances Their Antibody Developability Platform

Pierre Fabre Laboratories, a leading pharmaceutical and dermo-cosmetic company, sought to optimize its monoclonal antibody (mAb) candidate selection process. To achieve this, they needed a solution that could efficiently and accurately measure multiple physicochemical stability parameters.

By utilizing Prometheus Panta, they were able to streamline their developability platform, reducing complexity, cost, and sample consumption. The technology allowed them to gain a comprehensive view of their mAb's developability, enabling confident decision-making about candidates.

Discover how Pierre Fabre Laboratories successfully enhanced their antibody developability platform with Prometheus Panta. Download the full case study to learn about the specific benefits and results achieved, and explore how this technology can improve your mAb development process.